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OBJECTIVE—Arachidonic acid is metabolized by 12-lipoxygenase
(12-LOX) to 12-hydroxyeicosatetraenoic acid (12-HETE) and has
an important role in the regulation of angiogenesis and endothe-
lial cell proliferation and migration. The goal of this study was to
investigate whether 12-LOX plays a role in retinal neovasculari-
zation (NV).
RESEARCH DESIGN AND METHODS—Experiments were
performed using retinas from a murine model of oxygen-induced
ischemic retinopathy (OIR) that was treated with and without the
LOX pathway inhibitor, baicalein, or lacking 12-LOX. We also
analyzed vitreous samples from patients with and without
proliferative diabetic retinopathy (PDR). Western blotting and
RT-PCR were used to assess the expression of 12-LOX, vascular
endothelial growth factor (VEGF), and pigment epithelium–
derived factor (PEDF). Liquid chromatography–mass spectrome-
try was used to assess the amounts of HETEs in the murine retina
and human vitreous samples. The effects of 12-HETE on VEGF
and PEDF expression were evaluated in Müller cells (rMCs),
primary mouse retinal pigment epithelial cells, and astrocytes.
RESULTS—Retinal NV during OIR was associated with in-
creased 12-LOX expression and 12-, 15-, and 5-HETE production.
The amounts of HETEs also were signiﬁcantly higher in the
vitreous of diabetic patients with PDR. Retinal NV was markedly
abrogated in mice treated with baicalein or mice lacking 12-LOX.
This was associated with decreased VEGF expression and
restoration of PEDF levels. PEDF expression was reduced in
12-HETE–treated rMCs, astrocytes, and the retinal pigment epi-
thelium. Only rMCs and astrocytes showed increased VEGF ex-
pression by 12-HETE.
CONCLUSIONS—12-LOX and its product HETE are important
regulators of retinal NV through modulation of VEGF and PEDF
expression and could provide a new therapeutic target to prevent
and treat ischemic retinopathy. Diabetes 60:614–624, 2011
R
etinal neovascularization (NV) is a vision-
threatening complication of ischemic retinopa-
thy that develops in various retinal disorders,
including diabetic retinopathy and retinopathy
of prematurity (ROP). Retinal NV is controlled by a bal-
anced production of pro- and antiangiogenic factors, in-
cluding vascular endothelial growth factor (VEGF) and
pigment epithelium–derived factor (PEDF), respectively
(1). However, under some pathological conditions, in-
cluding diabetic retinopathy and ROP, this balance is dis-
rupted by enhanced production of proangiogenic and/or
downregulation of antiangiogenic factors (2,3).
Arachidonic acid metabolites, which are known as
eicosanoids, are involved in regulating angiogenesis (4).
Once released by cytosolic phospholipase A2 (5), arach-
idonic acid is metabolized via different pathways, in-
cluding the cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 pathways. Angiogenesis has been
shown to be promoted by the metabolic products of COX2,
prostaglandins (6) and the products of the lipoxygenase
system, leukotrienes, and hydroxyeicosatetraenoic acids
(HETEs) (7,8). LOXs are a group of closely related diox-
ygenases that catalyze the stereospeciﬁc oxygenation of
arachidonic acid and other polyunsaturated fatty acids
(PUFAs) and are classiﬁed as 5-, 8-, 12-, or 15-LOX,
according to the site of oxygen insertion within arach-
idonic acid.
Three types of 12-LOX have been characterized: platelet,
leukocyte, and epidermal 12-LOX (9), which are detected
in various cell types, including smooth muscle cells
(SMCs) (10), endothelial cells (10,11), and glial cells (12).
The major product of 12-LOX metabolism of arachidonic
acid, 12-HETE has a role in various biological processes,
including atherogenesis, cancer cell growth, and neuronal
apoptosis (13,14). In addition, 12-HETE has proinﬂammatory
effects (15,16) and has been implicated in diabetic vascular
complications (13). For example, high glucose treatment
increases 12-HETE production in vascular endothelial cells
and SMCs, and this increase is linked to vascular endothelial
growth factor (VEGF) upregulation (17,18) and leukostasis
(19) in the intracellular adhesion molecule-1–dependent
pathway (15). Similarly, 12-HETE has been shown to con-
tribute to tumor angiogenesis via a VEGF-dependent path-
way (20) and to stimulate endothelial cell mitogenesis (7,8)
and tube formation (21).
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ORIGINAL ARTICLEVEGF and PEDF are identiﬁed as key angiogenic factors
whose altered production contributes to the development
of retinal NV. They induce opposite effects in the retina,
which causes vasculopathies associated with diabetic ret-
inopathy and ROP. Although VEGF has angiogenic and
permeability effects that were shown to be mediated via
oxidative stress (22,23) and inﬂammatory pathways (24),
PEDF elicits antiangiogenic and antipermeability effects in
part through antioxidant (25,26) and anti-inﬂammatory
mechanisms (27). There are multiple cellular sources for
the growth factors involved in retinal NV. Müller cells
(rMCs) are known to express several modulators of an-
giogenesis by responding to hypoxia or hyperglycemia and
releasing VEGF (28,29). They also are shown to have an
antiangiogenic background attributed to PEDF secretion
(30). Moreover, VEGF and PEDF expression in rMCs are
altered by a high glucose concentration, which contributes
to retinal NV in diabetic retinopathy (31).
The role of lipoxygenases in general, and 12-LOX in
particular, in the development of retinal NV has not been
well investigated. The goal of this study was to explore the
changes in 12-LOX expression and activity during retinal
NV and to determine whether targeting 12-LOX activity
impacts retinal NV perhaps through changes in the level of
angiogenic factors.
The current study presents, for the ﬁrst time, that oxygen-
induced ischemic retinopathy (OIR) and proliferative
diabetic retinopathy (PDR) are associated with increased
12-LOX expression and activity. Inhibition of the LOX
pathway or 12-LOX deletion signiﬁcantly abrogated retinal
NV and VEGF expression, while preserving retinal PEDF
levels during OIR.
RESEARCH DESIGN AND METHODS
Animals. Wild-type C57BL/6J mice and 12-LOX–deﬁcient mice (B6.129S2-
Alox15 ,tm1Fun./J) were obtained from The Jackson Laboratory (Bar
Harbor, ME). Backcrossing of 12-LOX knockout mice with wild-type C57BL/6,
DNA extraction, and genotyping were performed according to the protocol
provided by The Jackson Laboratory using PCR. Animal experiments were
performed according to the Association of Research in Vision and Ophthal-
mology statement for the use of animals in vision research.
Vitreous samples. Human vitreous samples were obtained from the De-
partment of Ophthalmology, Medical College of Georgia, according to the
tenets of the Helsinki Declaration. After obtaining patient consent, vitreous
samples were collected from the eyes of individuals undergoing pars plana
vitrectomy as a treatment for PDR with tractional retinal detachment. The
control group comprised vitreous samples from eyes of patients who were
undergoing vitrectomy for nondiabetic causes. Vitreous samples were centri-
fuged for 5 min and processed for biochemical analysis.
Mouse model of OIR. Experiments were performed on wild-type C57BL/6J
and 12-LOX–deﬁcient mice. The groups comprised control, OIR wild type, OIR
treated with the LOX pathway inhibitor baicalein, and OIR 12-LOX–deﬁcient
mice. Retinal NV was developed as previously described (32). Murine pups
were incubated in high oxygen (75%) for 5 days, from postnatal day 7 to
postnatal day 12, followed by 5 days in room air (postnatal days 12–17). One
group of OIR mice was treated with baicalein (20 mg/kg/day i.p.) on postnatal
days 12–16. All mice were killed on postnatal day 17, and one retina was
collected from each animal for biochemical assays while the other eye
was harvested whole for morphological study. Additional experiments were
performed using db/db mice retinas. Six to eight-week-old mice received
streptozotocin (55 mg/kg). Mice with a glucose level of $250 mg/dL were
considered diabetic. The streptozotocin-induced db/db mice were maintained
for 8 weeks, then one eye of each animal was processed for frozen sections
and the retina of the other eye was frozen for protein analysis.
Liquid chromatography–mass spectrometry. Liquid chromatography–mass
spectrometry (LC/MS) was used to measure the amount of HETEs in murine
retina and vitreous samples. Samples were spiked with 10 ng 15(S)-HETE-d8
(internal standard), acidiﬁed to pH ,4 with dilute hydrochloric acid, applied
to preconditioned SEP-Pak C18 cartridges (100 mg adsorbent; Waters), and
washed with water followed by hexane. Eicosanoids were eluted with 500 mL
ethyl acetate. The eluate was dried under nitrogen and reconstituted in
methanol:25 mmol/L aqueous ammonium acetate (8:2). The extracted and
reconstituted sample was subjected to high-performance liquid chromatogra-
phy on a Max-RP C18 column (2 3 150 mm, 3m; Phenomenex). The com-
pounds were eluted isocratically with methanol:13 mmol/L aqueous
ammonium acetate (8:2) at a ﬂow rate of 0.4 mL/min. The eluent was moni-
tored for HETEs by a mass spectrometer (QuattroLC, Micromass) in the
negative ion mode using multiple-reaction monitoring for transitions of m/z
319 to m/z 115 for 5-HETE, m/z 179 for 12-HETE, and m/z 219 for 15-HETE
(source block: 120°C, desolvation: 350°C, cone voltage: 224 V, collision en-
ergy: 14 eV, and collision gas pressure: 3.2 3 10
24). 15(S)-HETE-d8 (MRM
transition of m/z 327 to 226 under identical conditions) was used as an internal
standard for recovery and quantitation. Retention times for 15-HETE (and 15
(S)-HETE-d8), 12-HETE, and 5-HETE were 2.6, 2.9, and 3.6 min, respectively,
and the detection limit was 50 pg for each compound on the column.
12-LOX immunolocalization. To localize the retinal expression of 12-LOX,
retinal frozen sections were ﬁxed by 2%paraformaldhyde, followedby blocking
the nonspeciﬁc reaction using normal goat serum. The sections then were
incubated with PBS containing the vascular marker isolectin-B4 (15 mg/mL
vector) and anti–12-LOX (1:100; Santa Cruz) followed by incubation with PBS
containing Texas red (25 mg/mL vector) and Oregon green secondary antibody
(1:500). Images were collected by confocal microscopy.
Assessment of new vessel formation. Retinal NV was assessed by labeling
retinal vasculature with isolectin-B4. Brieﬂy, the enucleated eye ball was ﬁxed
in 4% paraformaldhyde overnight, followed by dissecting the retina out of the
eyecup. Then,the retina wasincubated in PBScontaining 0.2%Triton-X100 and
15 mg/mL isolectin-B4 overnight. This was followed by washing with PBS and
incubation in PBS containing 25 mg/mL Texas red for 2 h. The retina was then
washed and ﬂat mounted on a slide. Vascular density was calculated using
Metamorph Imaging software. Metamorph was used to measure the area of
new blood-vessel formation as a percentage of total surface area in retinas.
Cell culture. rMC-1 was obtained as a gift from Dr. V. Sarthy (Northwestern
University, Chicago, IL). The cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (Mediatech/Cellgro) supplemented with 4.5 g/L glucose,
2 mmol/L L-glutamine, sodium pyruvate (DMEM:F12), penicillin/streptomycin,
and 10% FBS. To determine the effect of 12-HETE on VEGF and PEDF ex-
pression in rMC-1, different doses of 12-HETE (Cayman Chemical, Ann Arbor,
MI) were added to the cultured rMC-1 (0.5 mmol/L and 1 mmol/L 12-S-HETE
in serum-free DMEM:F12). By the end of the experiment (after 72 h), rMC-
conditioned medium and cell homogenate were collected and processed for
enzyme-linked immunosorbent assay (ELISA) and Western blotting analysis of
VEGF and PEDF expression, respectively.
Additional experiments were performed using murine retinal astrocytes and
retinal pigment epithelial (RPE) cells. Primary murine retinal astrocytes and
RPE cells were prepared as previously described (33). To determine the effects
of HETEs on VEGF and PEDF expression, retinal astrocytes and RPE cells
were plated. The next day, cells were washed with serum-free medium and
then incubated with 1.5 mL serum-free medium containing 1 mmol/L 5-, 12-, or
15-HETE. The next day, 0.5 mL of fresh HETE-containing medium was added
to each dish without removing the preconditioned medium. The next day, the
conditioned medium was collected for VEGF and PEDF measurements. The
cells were used for preparation of total RNA and quantitative PCR analysis, as
described below.
Western blotting. Western blotting was used to assess the expression of
12-LOX, VEGF, and PEDF in retina and retinal cells homogenate. The samples
TABLE 1
Primer sequences of PEDF and VEGF
Forward 59 to 39 Reverse 59 to 39
Calnexin NM_007597.3 GCTGCTGGTCCTTGGAACTG TCAATATCAATCGCGTCATCATC
PEDF NM_011340.3 GCCCAGATGAAAGGGAAGATT TGAGGGCACTGGGCATTT
VEGFA164 M95200.1 ATCTTCAAGCCGTCCTGTGTGC CAAGGCTCACAGTGATTTTCTGG
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 615FIG. 1. Analysis of 12-LOX expression in the retina. Western blot analysis of leukocyte (A) and platelet (B) 12-LOX showed signiﬁcant increases in
OIR compared with the control (C). *P < 0.05 vs. control. C: Immunolocalization using vascular marker (isolectin-B4, red) and anti–12-LOX
(green) showed a marked increase in 12-LOX immunoreactivity in retinal vessels (arrows) and RPE cells (arrowhead) of OIR compared with the
control (C). D: Western blot analysis of 12-LOX expression showed a signiﬁcant increase in retina of diabetic mice (D) compared with the control
(C). *P < 0.05 vs. control. E: Immunolocalization of 12-LOX (green) indicated that it is upregulated in retinal vessels (red) of diabetic mice (D).
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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mmol/L Tris-HCl, pH 7.4; 2.5 mmol/L ethylenediaminetetraacetic acid; 50 mmol/
L NaF; 10 mmol/L Na4P2O7; 1% Triton X-100; 0.1% sodium dodecyl sulfate; 1%
sodium deoxycholate; and 1 mmol/L phenylmethylsulfonyl ﬂuoride). Homo-
genates (40 mg protein) were separated by electrophoresis on a precast Tris-
HCl 4–20% gradient gel (Bio-Rad) and transferred to the nitrocellulose mem-
brane. Retina homogenates or cell lysate were reacted with different primary
antibodies, including platelet type 12-LOX (1:200; Santa Cruz Biotechnology),
leukocyte-type 12-LOX (1:1000; Abcam), VEGF (1:500), or PEDF (1:200; Santa
Cruz Biotechnology). Protein was detected by appropriate secondary horse-
radish peroxidase–conjugated antibody (Jackson Immuno Research) and en-
hanced chemiluminescence (Amersham). Membranes were stripped and
reprobed for b-actin to demonstrate equal loading, and the results were
quantiﬁed by densitometry analysis.
ELISA. ELISA was used to assess the levels of VEGF in the conditioned
medium using immunoassay kits as recommended by the supplier (Chemicon).
VEGF and PEDF quantitative PCR. The total RNA from the cells was
extracted by a mirVana PARIS kit (Ambion) according to the manufacturer’s
instructions. cDNA synthesis was performed from 1 mg total RNA using
a Sprint RT Complete-Double PrePrimed kit (Clontech). A total of 1 mL of each
cDNA (dilution 1:10) was used as a template in the quantitative PCR assays,
which were performed in triplicate on a Mastercycler Realplex (Eppendorf)
using the SYBR qPCR Premix (Clontech). Ampliﬁcation parameters were as
follows: 95°C for 2 min; 40 cycles of ampliﬁcation (95°C for 15 s, 60°C for 40 s);
and dissociation curve step (95°C for 15 s, 60°C for 15 s, and 95°C for 15 s).
Standard curves were generated from known quantities for each target gene
of linearized plasmid DNA. Ten times dilution series were used for each known
target, which were ampliﬁed using SYBR green quantitative PCR. The linear
regression line for each nanogram of DNA was determined from relative
ﬂuorescent units at a threshold ﬂuorescence value (Ct) to quantify gene targets
from cell extracts by comparing the relative ﬂuorescent units at the Ct to the
standard curve. Calnexin was used as a housekeeping gene to normalize all
samples. The primer sequences are listed in Table 1.
Statistical analysis. Group differences were evaluated using the t test or
ANOVA followed by a Tukey post hoc test. Results were considered signiﬁcant
when the P value was ,0.05. For in vivo studies, age-matched controls were
compared with the oxygen-treated mice treated with or without baicalein. For
the human study, diabetic subjects with PDR were compared with patients
who had a vitrectomy for other causes. For in vitro studies, four dishes were
prepared for each treatment group, and each experiment was replicated with
at least two different batches of retinal cells. Data were represented as
means 6 SE from at least six animals and subjects in each group and three
experiments from the in vitro study.
RESULTS
Increased 12-LOX expression and activity in OIR. To
determine whether 12-LOX plays a role in retinal NV, we
investigated its expression and activity in the murine
model of OIR, which is characterized by pathological ret-
inal NV. Retinal levels of leukocyte and platelet isoforms of
12-LOX were signiﬁcantly increased in OIR compared with
the control (Fig. 1A and B). Immunolocalization indicates
that 12-LOX is upregulated mainly in retinal vasculature
and RPE cells (Fig. 1C). There also was a signiﬁcant in-
crease in 12-LOX expression in diabetic retinas compared
with the control retinas (Fig. 1D) and, similar to OIR, 12-
LOX was localized mainly in retinal vasculature (Fig. 1E).
In addition, LC/MS analysis of 12-HETE in retinal
homogenates from normal and OIR mice showed signiﬁ-
cant increases in OIR compared with the control (35.3 6 6.
ng/mg vs. 10.2 6 2.0 ng/mg). This increase was signiﬁ-
cantly reduced in baicalein-treated and 12-LOX–deﬁcient
FIG. 2. LC/MS assay of HETEs production in mouse retina. There was a signiﬁcant increase in the amount of 12-HETE (A), 5-HETE (B), and 15-HETE
(C) in OIR compared with the control (C). The amount of 12-HETE was reduced in animals treated with baicalein or lacking 12-LOX (LOX
2/2).
*P < 0.05 vs. control; #P < 0.05 vs. OIR.
TABLE 2
Levels of 12-, 15-, and 5-HETE in selected control subjects and diabetic subjects with PDR
Patient diagnosis
Age (years)/sex
(male or female)
12-HETE
(ng/mL)
15-HETE
(ng/mL)
5-HETE
(ng/mL)
Traumatic retinal detachment 71/male 4.16 8.78 7.8
Epimacular membrane 27/male 20.7 55.3 6.2
Dislocated lens secondary to trauma 46/female 3.18 8.28 5.7
Idiopathic epimacular membrane 65/male 10.3 3.69 4.3
PDR, traction retinal detachment/diabetes, hypertension 60/male 42.1 63.8 72
PDR, traction retinal detachment/hypertension, heart disease 52/female 59 92.4 65
PDR, traction retinal detachment/diabetes, hypertension,
cerebello-spinal degeneration 41/male 12.8 47 25
PDR, traction retinal detachment/diabetes, hypertension 48/male 67.9 102 205
Advance PDR with traction retinal detachment
and vitreous hemorrhage/diabetes, hypertension 49/male 11.0 38.2 20
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(Fig. 2A). The association between increased expression
and activity of 12-LOX and retinal NV indicates that
12-LOX might be involved in the pathogenesis of ischemic
retinopathy. Despite the fact that the primary focus of our
study was on 12-LOX, we also noticed marked increases in
the amounts of 5-HETE and 15-HETE in OIR compared
with the control. Thus, 15- and 5-LOXs also may contribute
to retinal NV. Although deletion of 12-LOX did not signiﬁ-
cantly affect the 5- or 15-HETEs level in OIR, we noticed
a modest decrease in the amount of 5- and 15-HETEs by
baicalein treatment (Fig. 2B and C).
Increased 12-HETE production in the vitreous of
patients with PDR. To determine whether 12-LOX is in-
volved in NV associated with diabetic retinopathy, we also
tested the changes in 12-HETE production in vitreous
samples of diabetic subjects with PDR compared with the
amount produced in subjects without PDR. An LC/MS as-
say of HETEs (Table 2) demonstrated signiﬁcantly higher
levels of 12-HETE in diabetic subjects with PDR compared
with control patients (33.4 6 11.0 ng/mL vs. 8.0 6 3.0 ng/mL)
(Fig. 3A). We also tested the expression of 12-LOX in the
retina of two diabetic and nondiabetic eye-donor subjects.
We noticed a marked increase in the protein levels of both
leukocyte and platelet 12-LOX in diabetic subjects com-
pared with nondiabetic subjects (data not shown). In
addition, 15-HETE and 5-HETE also were markedly in-
creased in subjects with PDR compared with control
subjects (57.8 6 11.1 ng/mL vs. 12.3 6 6.2 ng/mL and
35.4 6 11.0 ng/mL vs. 4.5 6 0.8 ng/mL), respectively
(Fig. 3B and C). Taken together, our data from OIR and
subjects with PDR suggest that along with 12-LOX, 5-LOX
and 15-LOX also may play a role in retinal NV.
Attenuation of retinal NV by baicalein or deletion of
12-LOX. To conﬁrm the link between 12-LOX and retinal
NV, we investigated the effect of baicalein or 12-LOX de-
letion on retinal NV during OIR. Our experiments demon-
strated a signiﬁcant decrease in the total area of new
capillary tufts by baicalein or 12-LOX deletion compared
with the nontreated group (1.3 6 0.01 mm
2/retina and 3.9 6
0.5 mm
2/retina, respectively, vs. 7.1 6 0.3 mm
2/retina)
(Fig. 4), indicating that 12-LOX could be a target for
therapeutic intervention in ischemic retinopathy.
Effect of baicalein or 12-LOX deletion on VEGF and
PEDF expression. The VEGF and PEDF are key factors
in retinal vascular homeostsis, and their alterations occur
during retinal NV. We next determined the effects of bai-
calein or 12-LOX deletion on retinal expression of VEGF
and PEDF during OIR. Retinal expression of VEGF
(Fig. 5A and B) was signiﬁcantly higher in OIR compared
with age-matched control subjects. Administration of bai-
calein (Fig. 5A) or deletion of 12-LOX (Fig. 5B) attenuated
the increase in VEGF levels. In addition, OIR was associ-
ated with a reduction in the retinal levels of PEDF in com-
parison with the age-matched control subjects. Baicalein
treatment relatively restored the normal level of PEDF
in oxygen-treated mice (Fig. 5C). However, deletion of
12-LOX did not affect retinal level of PEDF in OIR (data
not shown).
Effect of 12-HETE on VEGF and PEDF levels in
retinal cells. Because rMCs play a crucial role in retinal
NV via secreting VEGF, we next tested the effect of
12-HETE on VEGF production in rMCs. There was a sig-
niﬁcant increase in VEGF production in the conditioned
medium of rMCs incubated with different concentrations of
12-HETE (0.5 and 1 mmol/L) compared with vehicle-treated
cells (366.5 6 18 pg/mL and 342.6 6 74 pg/mL vs. 142.5 6
25 pg/mL, respectively) (Fig. 6A). The increase in VEGF
production was observed as early as 12 h from the start of
the treatment up to 72 h. Furthermore, normal levels of
PEDF, as an angiostatic factor, may be required to prevent
retinal NV. PEDF normally is expressed by different retinal
cells, particularly RPE cells and rMCs. Thus, we also were
interested in determining the effects of 12-HETE on PEDF
FIG. 3. LC/MS assay of HETE production in human vitreous samples.
The amounts of 12-HETE (A), 15-HETE (B), and 5-HETE (C) were
increased in diabetic subjects with PDR compared with the control (C).
*P < 0.05.
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PEDF expression by 0.5 and 1.0 mmol/L 12-HETE com-
pared with the vehicle-treated group (0.09 6 0.01 mmol/L
and 0.19 6 0.03 vs. 0.3 6 06 mmol/L, respectively) (Fig. 6B).
Taken together, our in vivo and in vitro data suggest that
12-HETE plays a signiﬁcant role in retinal nevascularization
in ischemic retinopathy through modulation of retinal VEGF
and PEDF expression.
We also tested the effect of 12-, 5-, and 15-HETEs on
VEGF and PEDF expression in murine astrocytes and RPE
cells. Although 5-, 12-, or 15-HETE did not elicit signiﬁcant
changes on VEGF expression in the RPE cells (Fig. 7B),
only 12-HETE signiﬁcantly increased VEGF expression in
the astrocytes (Fig. 7A). HETEs demonstrated similar
effects on PEDF expression in murine RPE cells and
astrocytes. 12- and 5-HETEs abrogated PEDF expression
in RPE cells and astrocytes compared with the control and
15-HETE (Fig. 7C).
Quantitative PCR analysis of VEGF and PEDF mRNA
expression demonstrated no signiﬁcant changes by any
HETE treatment in murine astrocytes and RPE cells (Fig. 8).
Thus, the effects on the protein levels might be post-
transcriptional.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study to
describe changes in the expression and activity of 12-LOX
during pathological retinal NV such as in OIR and PDR.
The major ﬁndings of our study include 1) increased ex-
pression of 12-LOX and production of 12-HETE, as well as
15- and 5-HETEs during OIR and PDR; 2) attenuation of
VEGF expression and newly formed blood vessels during
OIR by baicalein or 12-LOX deletion; and 3) induction and
inhibition of VEGF and PEDF expression, respectively, in
cultured glial cells (rMCs and primary murine astrocytes)
by 12-HETE.
LOX products of arachidonate metabolism such as
12- and 15-HETE have been shown to have angiogenic
properties (34,35). 12-LOX has been implicated in tumor
angiogenesis (36) as well as endothelial cell proliferation
and tube formation (7,8). However, the contribution of
12-HETE to ischemia-mediated retinal NV needs further
investigation. The current study showed that OIR and
PDR, which are characterized by retinal NV, were associ-
ated with increased 12-LOX expression and production of
its metabolite 12-HETE. Interestingly, metabolites of 5- and
15-LOXs also were increased, indicating that the lip-
oxygenase pathway of arachidonic acid metabolism is
implicated in the pathogenesis of ischemic retinopathy.
Additional investigations are required to explore the spe-
ciﬁc role of each of the lipoxygenase products in mediating
new vessel formation.
It recently was reported that retinas from nondiabetic or
db/db mice neither produce leukotrieness nor 5-lipoxygenase
mRNA (37). Of note, autooxidation of PUFAs leads to gen-
eration of various HETEs (38). Thus, increased reactive
oxygen species production in ischemic or diabetic retina
FIG. 4. Whole-mount retinas labeled with vascular marker (isolectin-B4). The total area of new capillary tufts (arrows, circled area) was reduced
in baicalein-treated (OIR+baicalein) and 12-LOX knockout mice (OIR-12LOX
2/2) compared with the nontreated group (OIR-WT). *P < 0.05 vs. the
nontreated group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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idation of PUFAs. Increased production of 15- and 12-HETEs
in cultured human retinal endothelial cells (HRECs) sub-
jected to hypoxia recently has been reported (21). The same
study also tested the effect of 5-, 12-, and 15-HETEs on
HREC tube formation under normoxia. Although all three
HETEs induced HREC tube formation, the effect of 12- and
15-HETEs was higher than that of 5-HETE. Consistent with
this study, our in vivo data from the OIR model showed
as i g n i ﬁcant increase in the amounts of HETEs in association
with retinal NV. In addition, the amounts of HETEs also in-
creased in the vitreous samples of diabetic subjects with PDR
compared with those without PDR.
The mechanisms by which 12-HETE promotes angio-
genesis remain elusive. In agreement with other reports,
our studies demonstrated that the angiogenic effect of 12-
HETE could be mediated via enhanced VEGF expression.
This was further supported by the abrogation of new
vessel growth and VEGF expression in the OIR model by
baicalein or 12-LOX deletion. In addition, 12-HETE in-
creased VEGF production in rMCs and murine astrocytes.
Previous studies also have reported increased VEGF ex-
pression in vascular smooth muscle cells (17) and prostate
cancer cells (36) by 12-HETE. Thus, VEGF seems to be
crucial in mediating the angiogenesis-promoting effects of
12-HETE.
The cross-talk between 12-LOX and VEGF also has been
demonstrated by increased production of 12-HETE and its
receptor BLT2 expression in VEGF-activated endothelial
cells. The use of 12-LOX siRNA or baicalein attenuated
VEGF-induced angiogenesis, which was restored by the
addition of supplemental 12-HETE (41). Thus, in the retina,
a positive feedback between 12-HETE and VEGF derived
from endothelial cells and rMCs may exist. Recently,
12-LOX has been shown to regulate hypoxia-inducible
factor-1a, a transcription factor involved in regulating
VEGF expression under hypoxic conditions via the phos-
phatidylinositol 3-kinase/AKT-dependent mechanism (42).
Retinal NV is tightly controlled by balanced VEGF and
PEDF production. Disruption of this balance triggers new
vessel formation in ischemic retinas. We therefore tested
the effect of 12-HETE and baicalein on PEDF expression
in rMCs and during OIR, respectively. In addition to VEGF,
PEDF seemed to be another target of 12-LOX’s angiogenic
effect. The current study showed abrogation of PEDF level
in rMCs, murine astrocytes, and RPE cells by 12-HETE.
Furthermore, baicalein restored the normal level of PEDF
in retina of OIR, suggesting that 12-HETE’s angiogenic
effect is mediated by disrupting VEGF/PEDF homeostasis.
Despite the effect of HETE on VEGF and PEDF expression
in retinal cells, there was no signiﬁcant effect on either
VEGF or PEDF mRNA, indicating that HETEs in general
and 12-HETE in particular might modulate their expres-
sion at posttranscriptional level.
Baicalein is known to inhibit the lipoxygenase pathway.
Our data demonstrate a signiﬁcant reduction, in retinal
HETEs particularly, of 12-HETE by baicalein. Although
baicalein and deletion of 12-LOX reduced retinal NV in
OIR, we noticed a more inhibitory effect for baicalein
compared with 12-LOX deletion. In addition, although
FIG. 5. Western blot analysis of VEGF and PEDF in the retina. A and B: OIR in wild-type (WT) mice was associated with signiﬁcantly higher VEGF
expression compared with the control. The change in VEGF expression was prevented by baicalein (OIR+baicalein) or deletion of 12-LOX (OIR-
12LOX
2/2). C: PEDF expression was reduced in the nontreated group (OIR-WT) and was restored by baicalein. *P < 0.05 vs. control; #P < 0.05 vs.
the nontreated group.
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not show a similar effect, indicating that in addition to
targeting 12-LOX, baicalein might elicit its effect on retinal
NV and PEDF expression through different pathways.
Recently, baicalein administration to diabetic rats amelio-
rated diabetes-induced microglial activation, expression of
proinﬂammatory cytokines, and VEGF and signiﬁcantly
reduced vascular permeability within the retina (43). Al-
though 12-HETE induces a marked reduction in PEDF
level in cultured retinal cells, deletion of 12-LOX did not
restore the retinal level of PEDF. Whether this attributed
to the effect of 5-HETE, which abrogates PEDF levels in
vitro, needs to be clariﬁed.
In addition to its role in angiogenesis, the LOX pathway
plays a role in leukostasis and capillary degeneration as-
sociated with diabetic retinopathy. A recent study (44)
demonstrated that 5- or 12-LOX deletion reduced leuko-
stasis, an early sign of vascular injury in diabietic reti-
nopathy. Although deletion of 5-LOX reduced capillary
degeneration, 12-LOX deletion did not show the same
effect (44). Of note, the neovascular stage of diabetic
retinopathy is triggered by the hypoxia that develops in
response to capillary degeneration. Under hypoxic con-
ditions, there is more 12- and 15-HETEs production by
HRECs compared with 5-HETE (21), suggesting that 5-,
12-, and 15-HETEs are each required for different stages
of diabetic retinopathy. Taken together, we suggest that
12-HETE is more involved in mediating leukostasis and NV
in diabetic retinopathy. Whether this mediation is via tar-
geting circulating leukocytes or the recruiting hematopoetic
stem cells needs further investigation. In particular, hem-
atopoetic stem cells have been identiﬁed in the epiretinal
membrane of PDR patients (45) and could contribute to
retinal NV. 12-LOX products also upregulate key growth-
related signaling kinases (46), which are involved in
leukostasis and angiogenesis. For example, activation of
nuclear factor-kB (15), P38 mitogen-activated protein ki-
nase, and NADPH oxidase (47) are important mechanisms
linking 12-LOX to vascular complications of diabetes, such
as retinopathy and nephropathy.
FIG. 6. Effect of 12-HETE on the level of VEGF and PEDF expression in rMCs. A: VEGF level in rMC–conditioned medium was determined by
ELISA. There was a marked increase in the amounts of VEGF by 12-HETE (0.5 and 1 mmol/L) compared with the control (C). *P < 0.05 vs. control.
B: Western blot analysis of PEDF expression in rMCs. Note the decreased PEDF expression by 12-HETE (0.5 or 1.0 mmol/L) compared with the
control (C). *P < 0.05 vs. control.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 621FIG. 7. Effect of HETEs on VEGF and PEDF expression in primary mouse retinal astrocytes and RPE cells. ELISA assay of VEGF in cultured mouse
retinal astrocytes (A) and RPE cells (B). 12-HETE induced a signiﬁcant increase in VEGF expression of retinal astrocytes compared with the
control and 5-HETE– and 15-HETE–treated cells (*P < 0.05 vs. control, 5-, and 15-HETE). There was no effect on VEGF expression in RPE cells
incubated with any of the HETEs compared with the control. C: Western blot analysis of PEDF expression in RPE cells showed marked inhibition
by 12- and 5-HETE compared with the control and 15-HETE.
FIG. 8. Quantitative PCR analysis of VEGF (A) and PEDF (B) in murine RPE cells and retinal astrocytes. There was no signiﬁcant change in VEGF
or PEDF mRNA level of RPE cells or astrocytes incubated with different HETEs.
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acid metabolism is involved in mediating retinal NV via the
VEGF/PEDF balance disruption. Additional investigation is
required to identify the mechanism by which 12-HETE
modulates VEGF and PEDF expression in ischemic/
diabetic retinas. Interruption of the lipoxygenase pathway
could be a novel therapeutic intervention for prevention
and treatment of ischemic retinopathy.
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